Affordable Access

deepdyve-link
Publisher Website

Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma

Authors
  • Chen, Guo
  • Davies, Michael A.1, 2
  • 1 Department of Melanoma Medical Oncology
  • 2 The University of Texas M. D. Anderson Cancer Center
Type
Published Article
Journal
Hematology/Oncology Clinics of North America
Publisher
Elsevier
Publication Date
Jan 01, 2014
Identifiers
DOI: 10.1016/j.hoc.2014.03.001
Source
Elsevier
Keywords
License
Unknown

Abstract

While selective mutant BRAF inhibitors (BRAFi) have revolutionized the treatment for metastatic melanoma, the magnitude and duration of their clinical benefit are significantly undermined by de novo and acquired resistance. Functional studies, molecular characterization of clinical samples, and clinical trials are each providing insights into the landscape of resistance mechanisms in this disease. These findings have implications for the development of rational therapeutic approaches, and have identified several challenges that remain to be overcome in order to improve outcomes in patients with metastatic melanoma.

Report this publication

Statistics

Seen <100 times